In conclusion, by using the LINCS program, we discovered that a JAK2 inhibitor, ruxolitinib, can downregulate ALDH1A3 expression and inhibit cell proliferation and migration in cholangiocarcinoma cell lines. The gene discussed is ALDH1A3; the disease is cholangiocarcinoma.